Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans
申请人:Regen BioPharma, Inc.
公开号:US20180214413A1
公开(公告)日:2018-08-02
The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to humans.
Photocatalytic C–H Disulfuration for the Preparation of Indolizine-3-disulfides
作者:Songxin Wu、Dangzhong Hu、Xuegui Wan、Jiaji Zhao、Qiuxing He、Zhengquan Su、Hua Cao
DOI:10.1021/acs.joc.2c01871
日期:2022.12.16
variety of indolizine-3-disulfides with good yields. Trisulfide dioxides were explored as a high-efficient disulfuration reagent. This disulfuration reaction could be scaled up to grams. Mechanistic studies support a photoinduced pathway involving the generation of indolizine cationic radicals. A bulky alkyl substituent on terminal sulfur of trisulfide dioxide A was necessary for selective formation of
开发了中氮氢化合物的光催化 C-H 二硫化,为多种中氮氢化合物 3-二硫化物提供了一种具有良好收率的方法。三硫化物二氧化物被探索为一种高效的二硫化试剂。这种二硫化反应可以放大到克级。机理研究支持涉及中吲嗪阳离子自由基生成的光诱导途径。二硫化物 A 的末端硫上的大烷基取代基对于选择性地形成二硫化物而不是一硫化物是必要的。
Small molecule agonists and antagonists of NR2F6 activity in animals
申请人:Zander Therapeutics, Inc.
公开号:US10472351B2
公开(公告)日:2019-11-12
The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.
Small molecule agonists and antagonists of NR2F6 activity
申请人:ZANDER THERAPEUTICS, INC.
公开号:US11377442B2
公开(公告)日:2022-07-05
The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein.
Small molecule agonists and antagonists of NR2F6 activity in humans
申请人:KCL THERAPEUTICS, INC
公开号:US11324719B2
公开(公告)日:2022-05-10
The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to humans.